Answers are grounded in this paper and cite their sources.
Rapid advances in antibody-drug conjugates (ADCs) and an expanding clinical evidence base are reshaping treatment options for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). Randomized trials have demonstrated progression-free survival benefits over chemotherapy for individual ADCs in defined populations, including settings before and after metastatic chemotherapy. As additional ADCs become available and indications expand, attention is increasingly focused on whether individual agents can improve outcomes over endocrine-based regimens in selected endocrine-eligible patients and on which therapies beyond conventional chemotherapy may retain activity after ADC progression. Addressing these questions requires integration of clinical evidence with a mechanistic understanding of ADC activity and resistance. In this review, we summarize selected mechanisms of ADC action and critically examine the evolving clinical roles of individual agents across settings defined by prior therapy. We also discuss treatment strategies after ADC exposure and resistance mechanisms relevant to target and payload selection. Finally, we review exploratory studies of candidate biomarkers associated with clinical outcomes, ADC-based combinations, and next-generation designs, highlighting their biological rationale, emerging evidence, and priorities for further evaluation.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: